trastuzumab deruxtecan sold brand name enhertu antibodydrug conjugate consisting humanized monoclonal antibody trastuzumab herceptin covalently linked topoisomerase inhibitor deruxtecan derivative licensed treatment breast cancer gastric gastroesophageal trastuzumab binds blocks signaling epidermal growth factor receptor cancers rely growth additionally bound receptors antibody internalized cell carrying bound deruxtecan along interferes cells ability make dna structural changes replicate dna cell division leading dna damage cell attempts replicate destroying approved medical use united states december japan march european union january australia october trastuzumab deruxtecan first approved therapy us food drug administration fda targeted people breast cancer subtype subset breast trastuzumab deruxtecan indicated treatment adults unresectable unable removed surgery metastatic cancer cells spread parts body breast cancer received two prior regimens metastatic setting adults locally advanced metastatic gastric gastroesophageal junction adenocarcinoma received prior trastuzumabbased may indication revised include treatment adults unresectable metastatic breast cancer received prior regimen either metastatic setting neoadjuvant adjuvant setting developed disease recurrence within six months completing august indication revised include treatment unresectable metastatic breast common side effects nausea fatigue vomiting alopecia hair loss constipation decreased appetite anemia hemoglobin blood reference range decreased neutrophil count white blood cells help lead bodys immune system response fight infection diarrhea leukopenia white blood cells help immune system cough decreased platelet count component blood whose function react bleeding blood vessel injury clumping thereby initiating blood prescribing information trastuzumab deruxtecan includes boxed warning risk interstitial lung disease group lung conditions causes scarring lung tissues embryofetal interstitial lung disease pneumonitis including cases resulting death reported trastuzumab fda approved trastuzumab deruxtecan based results one clinical trial enrolling female participants unresectable andor metastatic breast cancer received two prior therapies metastatic participants heavily pretreated metastatic setting receiving two therapies prior receiving trastuzumab participants clinical trial received trastuzumab deruxtecan every three weeks tumor imaging obtained every six overall response rate reflects percentage participants certain amount tumor shrinkage median duration response efficacy evaluated multicenter openlabel randomized trial participants locally advanced metastatic gastric gej adenocarcinoma progressed least two prior regimens including trastuzumab fluoropyrimidine platinumcontaining total participants randomized receive trastuzumab deruxtecan mgkg intravenously every three weeks physicians choice either irinotecan paclitaxel efficacy based multicenter openlabel randomized trial enrolled participants unresectable andor metastatic breast cancer received prior trastuzumab taxane therapy metastatic disease developed disease recurrence within six months completing neoadjuvant adjuvant participants randomized receive either trastuzumab deruxtecan trastuzumab emtansine intravenous infusion every three weeks unacceptable toxicity disease randomization stratified hormone receptor status prior treatment pertuzumab history visceral fda approved trastuzumab deruxtecan treatment breast cancer based randomized multicenter open label clinical trial enrolled adult participants unresectable metastatic breast trial included two cohorts hormone receptor positive hr participants hormone receptor negative hr participants randomly received trastuzumab deruxtecan intravenous infusion every three weeks randomly received physicians choice chemotherapy eribulin capecitabine gemcitabine nab paclitaxel results showed improvement progressionfree survival overall survival people unresectable metastatic breast us food drug administration fda approved trastuzumab deruxtecan december application trastuzumab deruxtecan granted accelerated approval fast track designation breakthrough therapy fda granted approval enhertu daiichi december committee medicinal products human use chmp european medicines agency ema adopted positive opinion recommending granting conditional marketing authorization medicinal product enhertu intended treatment metastatic breast trastuzumab deruxtecan reviewed emas accelerated assessment program applicant medicinal product daiichi sankyo europe gmbh trastuzumab deruxtecan approved medical use european union january january us food drug administration fda granted accelerated approval trastuzumab deruxtecan treatment adults locally advanced metastatic gastric gastroesophageal gej adenocarcinoma received prior trastuzumabbased october therapeutic goods administration australia approved trastuzumab deruxtecan provisional registration indicated treatment adults unresectable metastatic breast cancer received two prior anti httpsenwikipediaorgwikitrastuzumabderuxtecan